Answers are grounded in this paper and cite their sources.
This pilot study investigated a new simplified OSA screening tool that could be used in primary care/GP settings – the “GPSS” tool – “General Practice Sleep Scale” and compared against common existing OSA screening tools. A convenience sample of patients attending the respiratory and sleep clinic in the Northern Territory of Australia were included if they completed the GPSS prior to undergoing a diagnostic polysomnography. The GPSS contained 9 questions to provide information on: sex, age, body mass index, neck circumference, snoring, witnessed apnoeas, morning tiredness, daytime sleepiness and presence of hypertension/diabetes/heart disease/depression. Presence of OSA was defined as an apnoea-hypopnoea index of ≥15/hour. The GPSS scoring was developed via log odds of regression predictions for each GPSS question upon OSA. 159 patients (65 % male, median age 45 years) were enrolled. A minimum score of 1 was assigned to GPSS questions, up to 5 for the strongest predictor (neck circumference). The median total GPSS score was 13 (IQR 9, 16) (maximum 22) and correlated strongly with OSA (AUC 0.812 (95 % CI 0.744, 0.881)). Categorised into low (0–7), moderate (8–13) or high risk (>13), a moderate or severe score had sensitivity 100, specificity 34.9 %. The GPSS significantly outperformed the Epworth Sleepiness Scale, Berlin questionnaire and OSA-50, and was comparable but slightly improved against the STOP-Bang. The proposed GPSS tool could be of use in general practice settings. Further prospective research is warranted to test the applicability and adaptability of the GPSS tool in wider population settings. • General practitioners play a critical role in identifying at risk patients with OSA. • Underdiagnosis of OSA continues in General Practice due to competing priorities. • A simplified OSA screening tool (GPSS) for use in General practice was developed. • This proposed OSA screening tool outperformed most existing OSA screening tools. • Further research is warranted to test the GPSS utility in wider populations.
No takes yet. Share an insight, caveat, or question.
Howarth et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: